摘要
目的:分析普乐沙福联合粒细胞集落刺激因子(G-CSF)动员淋巴瘤患者自体外周血造血干细胞的有效性及安全性。方法:回顾性分析2019年1月到2021年12月接受普乐沙福联合G-CSF进行自体造血干细胞动员的淋巴瘤患者的临床资料。普乐沙福的用药策略分为一线稳态动员、抢先干预及挽救性动员,对三种策略的采集成功率、优良率及治疗相关不良反应率进行统计,并对性别、年龄、疾病缓解状态、初诊时是否有骨髓累及、化疗线数、化疗次数、采集前一天血小板数及采集前一天外周血CD34+细胞数等因素对采集结果的影响进行分析。结果:共纳入43例患者,其中7例为一线稳态动员,19例为抢先干预,17例为挽救性动员。使用普乐沙福联合G-CSF后,总体采集成功率为58.1%(25/43),一线稳态动员采集成功率为100%,抢先干预为57.9%(11/19),挽救性动员为41.2%(7/17)。采集优良率为18.6%(8/43)。共有15例患者出现轻中度治疗相关不良反应。采集前一天外周血CD34+细胞数<5个/μl是影响干细胞采集的独立危险因素。结论:普乐沙福联合G-CSF是淋巴瘤患者安全有效的动员方案。采集前一天外周血CD34+细胞数是预测干细胞采集的有效指标。
Objective:To investigate the efficacy and safety of plerixafor combined with granulocyte colonystimulating factor(G-CSF)in mobilizing peripheral blood hematopoietic stem cells in patients with lymphoma.Methods:The clinical data of lymphoma patients who received autologous hematopoietic stem cell mobilization using plerixafor combined with G-CSF from January 2019 to December 2021 were retrospectively analyzed.The patients received 3 kinds of mobilization regimens:front-line steady-state mobilization,preemptive intervention,and recuse mobilization.The acquisition success rate,excellent rate of collection,and incidence of treatment-related adverse reaction were counted.The influence of sex,age,disease remission status,bone marrow involvement at diagnosis,chemotherapy lines,number of chemotherapy,platelet count and number of CD34^(+)cells on the day before acquisition in peripheral blood on the collection results were analyzed to identify the risk factors associated with poor stem cell collection.Results:A total of 43 patients with lymphoma were enrolled,including 7 cases who received front-line steady-state mobilization,19 cases who received preemptive intervention,and 17 cases who received recuse mobilization.The overall acquisition success rate was 58.1%(25/43)after use of plerixafor combined with G-CSF,and acquisition success rate of front-line steady-state mobilization,preemptive intervention,and recuse mobilization was 100%,57.9%(11/19),and 41.2%(7/17),respectively.The excellent rate of collection was 18.6%(8/43).A total of 15 patients experienced mild to moderate treatment-related adverse reactions.The number of CD34^(+)cells<5 cells/μl in peripheral blood on the day before collection was an independent risk factor affecting stem cell collection.Conclusions:Plerixafor combined with G-CSF is a safe and effective mobilization regimen for patients with lymphoma.The number of CD34^(+)cells in peripheral blood on the day before collection is an predictable index for the evaluation of stem cell collection.
作者
管方舒
何冬花
李奕
张仪
郑高锋
朱园园
何静松
张恩帆
蔡真
赵毅
GUAN Fang-Shu;HE Dong-Hua;LI Yi;ZHANG Yi;ZHENG Gao-Feng;ZHU Yuan-Yuan;HE Jing-Song;ZHANG En-Fan;CAI Zhen;ZHAO Yi(Bone Marrow Transplantation Center,Zhejiang University School of Medicine,Hangzhou 310006,Zhejiang Province,China;Department of Hematology,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310006,Zhejiang Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2023年第4期1056-1060,共5页
Journal of Experimental Hematology
关键词
普乐沙福
淋巴瘤
外周血造血干细胞
造血干细胞动员
CD34
plerixafor
lymphoma
peripheral blood hematopoietic stem cell
hematopoietic stem cell mobilization
CD34
